Cauchi M N, Lim D, Young D E, Kloss M, Pepperell R J
Royal Women's Hospital, Melbourne, Australia.
Am J Reprod Immunol. 1991 Jan;25(1):16-7. doi: 10.1111/j.1600-0897.1991.tb01057.x.
A paired sequential trial was undertaken to establish whether paternal mononuclear cells improved the prognosis in couples with recurrent abortions. For this purpose, 10(7)-10(8) cells obtained from the blood of partners were injected intravenously, subcutaneously, and intra-dermally into women who had had three or more consecutive miscarriages with the same partner. Control women were given normal saline, injected in the same manner. The result of the sequential analysis showed that there was no significant beneficial effect of the cells compared to control. The overall success rate was 70% (32/46 couples). The success rate in patients given cells was 62% (13/21), while in those given saline it was 76% (19/25). While the overall success rate in this study compares with a number of other studies, we find an equally high success rate with non-immunized patients. We conclude that the value of immunization for the prevention of recurrent miscarriage has not been established.
进行了一项配对序贯试验,以确定父亲的单个核细胞是否能改善反复流产夫妇的预后。为此,从伴侣血液中获取的10(7)-10(8)个细胞通过静脉、皮下和皮内注射到与同一伴侣连续发生三次或更多次流产的女性体内。对照组女性以相同方式注射生理盐水。序贯分析结果显示,与对照组相比,细胞没有显著的有益效果。总体成功率为70%(46对夫妇中的32对)。接受细胞注射的患者成功率为62%(21例中的13例),而接受生理盐水注射的患者成功率为76%(25例中的19例)。虽然本研究的总体成功率与其他一些研究相当,但我们发现未进行免疫治疗的患者成功率同样很高。我们得出结论,免疫预防反复流产的价值尚未确立。